Biologische Therapie beim fortgeschrittenen 
Lungenkarzinom

Literatur
1 Barlesi F, Blons H, Beau-Faller M et al. Biomarkers (BM) France: Results of routine EGFR, HER2, KRAS, BRAF, PI3KCA mutations detection and EML4-ALK gene fusion assessment on the first 10,000 non-small cell lung cancer (NSCLC) patients (pts). J Clin Oncol 2013; 31 Abstr. 8000
2 Doebele RC, Vaishnavi A, Capelletti M et al. NTRK1 gene fusions as a novel oncogene target in lung cancer. J Clin Oncol 2013; 31 (Suppl. 01) Abstr. 8023
3 Drilon A, Rekhtman N, Ladanyi M et al. Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy. Lancet Oncol 2012; 13: e418-e426
4 Felip E et al. Phase II activity of the HSP90 Inhibitor AUY922 in patients with ALK-rearranged (ALK+) or EGFR-mutated advanced non-small cell lung cancer (NSCLC). Ann Oncol 2012; 23 (Suppl. 09) Abstr. 4380
5 Jänne PA, Shaw AT, Pereira JR et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer. Lancet Oncol 2013; 14: 38-47
6 Johnson BE, Kris MG, Berry LD et al. A multicenter effort to identify driver mutations and employ targeted therapy in patients with lung adenocarcinomas: The Lung Cancer Mutation Consortium (LCMC). J Clin Oncol 2013; 31 (Suppl. 01) Abstr 8019
7 Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363: 1693-1703
8 MacConaill LE. Existing and emerging technologies for tumor genomic profiling. J Clin Oncol 2013; 31: 1815-1924
9 Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380-2388
10 Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-995
11 Paez JG, Jänne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500
12 Planchard D, Mazieres J, Riely GJ et al. Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation–positive non-small cell lung cancer (NSCLC) patients. J Clin Oncol 2013; 31 (Suppl. 01) Abstr 8009
13 Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC). Lancet Oncol 2012; 13: 239-246
14 Schuette W, Eberhardt W, Graf von der Schulenburg JM et al. Reason: A registry for the epidemiologic and scientific evaluation of EGFR mutation status in newly diagnosed NSCLC patients stage IIIB/IV in Germany. J Thorac Oncol 2011; 6: S1244 (abstr. P3.122)
15 Sequest LV, Yang JC, Yamamoto N et al. A phase III study of afatinib or cisplatin plus pemetrexed in patients with lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013; Jul 1. (Epub ahead of print)
16 Shaw AT, Kim DW, Nakagawa K et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013; 368: 2385-2394
17 Shaw AT, Mehra R, Kim DW et al. Clinical activity of the ALK inhibitor LDK378 in advanced, ALK-positive NSCLC. J Clin Oncol 2013; 31 (Suppl. 01) Abstr 8010
18 Socinski MA, Goldmann J, El-Hariry I et al. A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res 2013; 19: 3068-3077
19 Soda M, Choi YL, Enomoto M et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448: 561-566
20 Surati M, Patel P, Peterson A et al. Role of MetMAb (OA-5D5) in c-MET active lung malignancies. Expert Opin Biol Ther 2011; 11: 1655-1662
21 Takeuchi K, Soda M, Togashi Y et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med 2012; 18: 378-381
22 Wieweg M, Ting S, Reis H et al. Feasibility of preemptive biomarker profiling for personalised early clinical drug development at a Comprehensive Cancer Center. Eur J Cancer 2013; Jul 19. (Epub ahead of print)
23 Engelmann JA, Chen L, Tan X et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancer. Nat Med 2008; 14: 1315-1316